Key Highlights

  • Coiled Therapeutics Plc (LSE:COIL) is a clinical-stage precision oncology company that joined AIM in 2026 after a reverse takeover of Roquefort Therapeutics.
  • Its lead asset, AO-252, is a first-in-class small molecule inhibitor of TACC3 in a Phase I trial in the United States for advanced solid tumours.
  • The share price has retreated sharply from its 52-week high of 30p, trading below 8p in late September 2026.
  • Investors are watching for clinical updates, funding news and progress on the STAT-6 siRNA immunology programme.

Why Coiled Therapeutics Is in Focus Today

Coiled Therapeutics Plc (LSE:COIL), the AIM-listed precision oncology company, is attracting fresh attention from UK biotech investors on 12 October 2026. After a steep share price decline over the past year, the stock has become a talking point on social media investing forums, where traders are debating whether the market has fully priced the potential of its lead cancer drug.

The shares were quoted around 7.90p in late September 2026, well below the 30p peak reached in November 2025. That gap, combined with an active Phase I trial, is keeping LSE:COIL on small-cap watchlists as investors wait for the next set of clinical milestones.

From Roquefort to Coiled

Coiled Therapeutics was previously called Roquefort Therapeutics. The business changed shape through a reverse takeover in which it acquired an exclusive worldwide licence to AO-252 and readmitted its shares to trading on AIM under the ticker COIL. The underlying operating business was spun out of US-based A2A Pharmaceuticals in 2025.

The company is led by Executive Chairman Dr Sotirios Stergiopoulos and Chief Executive Sridhar Vempati. Alongside its London quote, the shares are cross-traded on the OTCQB Venture Market in the United States, which widens access for North American investors.

Coiled's scientific thesis centres on targeting proteins historically considered "undruggable", particularly coiled-coil and other structurally complex cancer drivers. Management believes the next wave of precision medicine will come from reaching these difficult targets.

AO-252: A First-in-Class Approach

AO-252 is a small molecule designed to inhibit TACC3, a protein involved in cell division that is overexpressed in a range of cancers. The drug is currently in a Phase I clinical trial in the United States for patients with advanced solid tumours, including ovarian and prostate cancer, whose disease has progressed on other treatments.

Phase I trials are designed mainly to establish safety, tolerability and dosing, although early signs of anti-tumour activity are closely watched. Because AO-252 is described as first-in-class, any clinical signal would carry significance, as there is no approved TACC3 therapy on the market.

Patient enrolment is ongoing, and the company has said it is testing for both safety and efficacy in patients whose cancer has advanced despite earlier therapies.

A Second Shot on Goal in Immunology

Beyond oncology, Coiled holds a STAT-6 siRNA programme aimed at immunology indications such as asthma, fibrosis, eczema and allergic disease. The programme is being assessed for progression towards Phase I trials. While earlier stage, it offers diversification away from a single-asset story and could become a candidate for partnering.

Share Price and Valuation Context

With around 426.8m shares in issue, a share price near 8p implies a market capitalisation in the region of £34m. The stock has traded in a 52-week range of roughly 6.5p to 30p, reflecting the high volatility typical of early-stage biotech companies.

Coiled does not generate revenue and does not pay a dividend. Its value rests on clinical progress, intellectual property and the ability to fund development until data can attract partners or larger investors. That makes funding headlines and cash runway particularly important for LSE:COIL holders.

Sector Backdrop

Precision oncology remains one of the most active areas of global drug development, with large pharmaceutical companies regularly licensing early-stage assets that show novel mechanisms. At the same time, funding for small biotech companies has been selective, and AIM-listed developers often face pressure until they can show meaningful human data.

What Investors Are Watching Next

The most important catalyst is clinical news from the AO-252 Phase I study, including dose-escalation progress, safety findings and any early efficacy signals. Investors will also watch for the company's next financial report, which should clarify cash resources and spending plans.

Other potential triggers include partnership discussions, progress in moving the STAT-6 programme towards the clinic, additional patent coverage and any capital raising. How the company balances the need for funding against shareholder dilution will be a central question.

Outlook

Coiled Therapeutics (LSE:COIL) offers exposure to a first-in-class cancer drug at a very early stage of development. The share price slide has reset expectations, and the next leg of the story depends on clinical evidence. Until data arrives, the stock is likely to remain sensitive to news flow, sentiment across AIM biotech and broader appetite for early-stage risk.